The Helsinki Heart Study: basic design and randomization procedure

Area of Science:

• Cardiovascular Medicine
• Clinical Trials
• Lipid Metabolism

Background:

• Coronary heart disease (CHD) prevention is crucial in middle-aged men with lipid abnormalities.
• Existing trials may not fully address simultaneous lipid profile modification.
• The Helsinki Heart Study addresses this gap by evaluating gemfibrozil's impact.

Purpose of the Study:

• To assess the efficacy of gemfibrozil in reducing coronary heart disease incidence.
• To evaluate gemfibrozil's effect on lowering total and LDL-cholesterol while raising HDL-cholesterol.
• To analyze these effects over a 5-year intervention period.

Main Methods:

• A 5-year primary prevention trial involving 4081 middle-aged men with lipid abnormalities.
• Randomized allocation to gemfibrozil (600 mg twice daily) or placebo.
• All participants received a cholesterol-lowering diet; randomization balanced key risk factors.

Main Results:

• Baseline data from 4081 participants with mean total cholesterol 7.5 mmol/L and HDL-cholesterol 1.23 mmol/L.
• Participants exhibited significant lipid abnormalities, hypertension (15%), and smoking (36%).
• The study successfully randomized participants, balancing major risk factors between groups.

Conclusions:

• The Helsinki Heart Study provides a robust design for evaluating gemfibrozil's cardioprotective effects.
• Baseline data and randomization success are detailed for future outcome analysis.
• Comparison with other major preventive trials offers insights into study design methodologies.